BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36292985)

  • 1. Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells-EGFRvIII Appears as a Weak Oncogene.
    Włodarczyk A; Tręda C; Rutkowska A; Grot D; Dobrewa W; Kierasińska A; Węgierska M; Wasiak T; Strózik T; Rieske P; Stoczyńska-Fidelus E
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma.
    Katanasaka Y; Kodera Y; Kitamura Y; Morimoto T; Tamura T; Koizumi F
    Mol Cancer; 2013 Apr; 12():31. PubMed ID: 23617883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells.
    Mut M; Lule S; Demir O; Kurnaz IA; Vural I
    Int J Biochem Cell Biol; 2012 Feb; 44(2):302-10. PubMed ID: 22085529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
    Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
    Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
    Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
    Li L; Puliyappadamba VT; Chakraborty S; Rehman A; Vemireddy V; Saha D; Souza RF; Hatanpaa KJ; Koduru P; Burma S; Boothman DA; Habib AA
    Oncogene; 2015 Jan; 34(1):129-134. PubMed ID: 24362532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR
    von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M
    Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
    Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
    Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.
    Stec WJ; Rosiak K; Siejka P; Peciak J; Popeda M; Banaszczyk M; Pawlowska R; Treda C; Hulas-Bigoszewska K; Piaskowski S; Stoczynska-Fidelus E; Rieske P
    Oncotarget; 2016 May; 7(22):31907-25. PubMed ID: 27004406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
    Estrada-Bernal A; Lawler SE; Nowicki MO; Ray Chaudhury A; Van Brocklyn JR
    J Neurooncol; 2011 May; 102(3):353-66. PubMed ID: 20938717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells.
    Choi D; Montermini L; Kim DK; Meehan B; Roth FP; Rak J
    Mol Cell Proteomics; 2018 Oct; 17(10):1948-1964. PubMed ID: 30006486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of extracellular-regulated kinases by normal and mutant EGF receptors.
    Lorimer IA; Lavictoire SJ
    Biochim Biophys Acta; 2001 Feb; 1538(1):1-9. PubMed ID: 11341977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.
    Li L; Chakraborty S; Yang CR; Hatanpaa KJ; Cipher DJ; Puliyappadamba VT; Rehman A; Jiwani AJ; Mickey B; Madden C; Raisanen J; Burma S; Saha D; Wang Z; Pingle SC; Kesari S; Boothman DA; Habib AA
    Oncogene; 2014 Aug; 33(33):4253-64. PubMed ID: 24077285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
    Feng H; Hu B; Jarzynka MJ; Li Y; Keezer S; Johns TG; Tang CK; Hamilton RL; Vuori K; Nishikawa R; Sarkaria JN; Fenton T; Cheng T; Furnari FB; Cavenee WK; Cheng SY
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3018-23. PubMed ID: 22323579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.